1 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Famewave Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion - Solid Tumor, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Famewave Ltd. | 79 | 2021-03-19 | 2024-12-27 |
| Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) CM-24 (MK-6018), Pembrolizumab (MK-3475) - Non-small Cell Lung Carcinoma (NSCLC), Melanoma | Phase 1 | Terminated | Famewave Ltd. | 27 | 2015-02-01 | 2020-08-27 |
Carcinoma, Non-Small-Cell Lung (2) · Melanoma (2) · Ovarian Neoplasms (2) · Adenocarcinoma (1) · Colorectal Neoplasms (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1) · Thyroid Cancer, Papillary (1) · Urinary Bladder Neoplasms (1)
Nivolumab (1) · Taxes (1) · pembrolizumab (1)
Israel (2) · United States (2) · Spain (1)